1. Home
  2. MNY vs SCLX Comparison

MNY vs SCLX Comparison

Compare MNY & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$0.83

Market Cap

58.9M

Sector

N/A

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$7.11

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
SCLX
Founded
2014
2011
Country
Singapore
United States
Employees
240
34
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
52.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNY
SCLX
Price
$0.83
$7.11
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
57.1K
98.1K
Earning Date
04-30-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
$19.58
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$4.20
52 Week High
$2.40
$34.27

Technical Indicators

Market Signals
Indicator
MNY
SCLX
Relative Strength Index (RSI) 17.22 48.13
Support Level N/A $5.72
Resistance Level $1.50 $7.77
Average True Range (ATR) 0.13 0.86
MACD -0.04 -0.06
Stochastic Oscillator 4.72 42.32

Price Performance

Historical Comparison
MNY
SCLX

About MNY MoneyHero Limited

MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: